Member Info for TorquayFan

Hi Cleaner - that's new to me.

Hello Cleaner/C11. Cleaner I'm afraid I see the point that C11 is making.

Re. your : "I like to read and like joining dots and seeing connections". Yes but you are 'joining dots' when there is no indication that they have relation at all to each other, making unfounded assumptions of a connection and even now, suggesting that this is indicative of a 'pipeline' of coming RNS - with respect, that is fantasy.

Thanks for your efforts but please . . . . . . ATB

. . . "It’s the only lab in Texas named as a prime contractor for the Biomedical Advanced Research and Development Authority, a designation that has positioned the institute for a $100 million portfolio of potential work, he added.

In addition, Texas Biomed has decades of experience conducting regulated, high-containment science required for FDA approval of drugs and vaccines. That, coupled with the inroads it’s made internationally, could draw significantly more business to San Antonio.

“We're playing on a global stage,” Hallam said. Its work with Scancell could draw more international attention. Unlike the Pfizer and Moderna Covid-19 vaccines that use messenger RNA, or mRNA, to cue the immune system to produce antibodies, Scancell’s vaccine platform uses sections of viral DNA to achieve a similar result. “There is always a need to develop new or improve on existing vaccines to ensure we have effective tools to counter emerging variants,” Texas Biomed Innovation Lab Principal Investigator Viraj Kulkarni said. “DNA vaccines are one of the promising alternatives because they are adaptable, simple to generate and effective.” Scancell’s vaccine was tested on mice at Texas Biomed.

“Texas Biomed has the biocontainment facilities and expertise to test our products,” said Samantha Paston, head of translational sciences for the U.K. company. “Covid's here forever. So, there is ongoing activity to continue looking at alternate technologies that have broader effectiveness against viruses,” Hallam said. “We want to be part of that.”

https://www.bizjournals.com/sanantonio/news/2023/09/11/texas-biomed-drug-maker-covid.html

Some 'positives' at last for Covidity and it seems that Texas Biomed have been active in their interest - "Scancell’s vaccine was tested on mice at Texas Biomed".

GLA

Thanks to you Baz and also to the hardworking Marcus on PoG 5705 who has unearthed the script for us :-

"Texas Biomed teams with UK drug maker amid new Covid threats

More companies are seeking out the SA institute's help as it garners a wider global reputation post-pandemic. Cory Hallam, vice president of business development and strategic alliances for Texas Biomedical Research Institute, says the organization's investments and expertise are paying off in new business.

TEXAS BIOMED By W. Scott Bailey – Senior Reporter, San Antonio Business Journal Sep 11, 2023

As health officials deal with new Covid-19 variants and the possibility of another wave of outbreaks, more drugmakers are working to move novel vaccines to market. And some of them are turning to the Texas Biomedical Research Institute in San Antonio for help. Texas Biomed’s development of a new Innovation Lab in 2021 has positioned the institute to take on more of that work.

“At the onset of Covid, worldwide demand for quality science went through the roof. As an institute with an 80-year history of doing the deep bench science, we realized we had the skill, the capacity and the tools to provide a response to that,” Texas Biomed Vice President for Business Development and Strategic Alliances Cory Hallam said. “So, we set up the lab.” That investment is paying off. One of the latest clients to reach out to Texas Biomed for an assist is Scancell Ltd., a U.K. company working to develop a new DNA-based Covid vaccine. The two entities have completed a joint preclinical study showing its effectiveness at protecting against the virus. Such work, Hallam says, is helping accelerate the science needed to bring promising drugs to market. There is a niche for Texas Biomed and its expertise, he noted, as the academic environment doesn’t always move at the pace companies need in times like this.

Rising concerns spawning more science. Health officials have their eye on multiple new Covid variants, including EG.5 and BA.286. In August, the World Health Organization classified the former as a variant of interest.

On Monday, the U. S. Food and Drug Administration approved the authorization of emergency use updated Covid-19 vaccines formulated to more closely target newer variants and to provide better protection against the virus. Meanwhile, more drug companies are enlisting Texas Biomed’s help — in part because of its investment in the Innovation Lab.

“We learned in the pandemic that the ability to move quickly was critical,” Texas Biomed President and CEO Larry Schlesinger said. “This new Innovation Lab was set up with both scientific rigor and nimbleness in mind in order to satisfy the increasing number of public and private partners that are wanting to work with Texas Biomed.”

(cont'd)

Sorry Moonparty - from B's link, how do you conclude ?

11.16 - "Good spot Bazookajr, seems covidity is still a valuable asset."

ATB

Cleaner ?

12.01 - "I don't this one goes to stand before her eminent peers to talk about"

12.04 - "I don't this LD would go and deliver her life work and experience before"

As I see it Bermuda will continue to post here sometimes and I am one of those who value the informed focus and clarification he brings, often when the BB might be heading down a more or less blind alley - so thanks for him for that.

Crumbs has always been a valued Poster but on 'that' day, I think he rather overdid the disappointment - anger apparent. But I think to question his sincerity was misguided and off target. Crumbs I hope you will continue to post when you feel you can.

Cleaner I don't share your suspicions and hope you will back off and as for Ahananda, he seems intent on wreaking havoc here so I'm about to exercise the good old filter.

Crumbs, hope to see you here again. Nice weekend all . . . . .

Re. BDO Mandeep - thanks RW - the 'research' was OK, the typing wasn't. September should be an interesting month, hopefully. Some more blue would not go amiss.

A jolly great welcome to Mandeep (and Sath again) as the team goes from strength to strength . . . . its been a long wait for Mandeep to arrive and I suggest that he (and our CEO) knows what he's doing and exactly what the opportunities are at Scancell. GN

All power to them both and all.

Crumbs, I'm sure your posting has been straightforward throughout and I don't myself impugn your motives at all. On 'that' day, it seemed to me that you got angry/disappointed and showed it, but I agree that you should not be taking stick. And the critics seem to only make it worse as you repeat your points.

I think your email to Scancell might have 'registered' so thanks for that.

Oh and I hope you get fully back in asap - you wouldn't want to be out of this over the weekend !! (wink) Flying tonight so BFN

Thanks for that WTP . . . . Also - its good to see a little bounce back. It's going to be an interesting month. CFO on seat now - waiting for the CBO !

Crumbs - 'whats the new CEO for' ? You mean CFO ?

I think the long established CEO has a mega full agenda of science and other various matters !

September will be interesting . . . . .

Aptly named AHA ! Crumbs has been a knowledgeable and helpful poster for many years here. Shooting him with his message won't help - in fact it entrenches a defence that you don't want to hear - right or wrong.

As it happens, my simple opinion is that Crumbs over-reacted to the initial news and as a respected poster, we noticed !

Whatever, all to play for here and I greatly enjoyed a balanced look from Burble so thanks to him for that.

Ruck that you think the CFO is there to 'count the beans' says it all . . .

MMmmm - hopefully she or he can get to work SOON !

Ruck NO it wasn't greeted that way !!

I'd say it was greeted with balanced interest . .

You ought to try it !

Good point Kash but as for this, "making me wonder if he can hold a job down" my thoughts are, 'yes he's moved around but he always seems to be able to get another job!' Which is a strength indeed.

Thanks for your revelations about BTG - MMMmmmm

Marcus has posted this on the other side - "Chief Financial Officer, Sath Nirmalananthan said : "I am excited to be joining Scancell at such a pivotal time. With the Phase 2 single arm SCOPE trial progressing and initial topline data readouts expected this year and Modi-1 next year, the Company is positioned with highly valuable science and near-term inflection points that should deliver value to our shareholders. I look forward to working with Lindy and the wider team and am excited by the potential of what can be achieved." "

Thanks Marcus - other thoughts : communications wise, coincidentally this looks to cover much of what Crumbs and others were asking for, (Crumbs in his memo to Prof. Lindy after the last RNS). And, apparently Sath believes we are at 'such a pivotal time' - now where have I heard that before? Scancell looks full speed ahead?

Just to add a well done to our CEO - good move !

Time will tell.

Crumbs I agree with you that this is a good RNS. Sath interestingly has a BSc in Pharmacology, (better than nothing but it won't take him too far at the level of THIS science), in an unusual combination of skills, he being a Chartered Accountant.

Of relevant note, "Sath worked at Reckitt where he was Finance Director for Group Reporting and subsequently for eCommerce in Reckitt's Health Division." So Sath is familiar with 'presenting' and reporting and is experienced in eCommerce - it suggests he is 'savvy' with communication skills.

Last I'd note my guess that Sath will not have come cheap with this background and pedigree. For me this appointment indicates that at least the BoD have good confidence in the immediate and longer term future - it's good they are not economising on the quality of the team to 'beef up' Scancell in every respect. For me it's very encouraging and I look forward even more to the disclosure of the new BDO, who I'm guessing will be another quality appointment who won't 'come cheap' either.

It looks a very positive indicator to me - maybe the next tranche from Genmab is expected soon ? All good fun . . .

"Sath Nirmalananthan is an experienced finance professional with over 15 years experience across healthcare in FTSE and NASDAQ listed companies, investment banking and audit. Before joining Scancell, Sath was Chief Financial Officer for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven health sciences company. Prior to that, Sath worked at Reckitt where he was Finance Director for Group Reporting and subsequently for eCommerce in Reckitt's Health Division. Sath has also held senior positions at BTG plc, a specialty pharmaceutical company, including Director of Group Reporting and Director of FP&A of interventional oncology. Earlier in his career, he was an equity research analyst in the healthcare team at Nomura and prior to that an auditor at KPMG. Sath earned a BSc in Pharmacology from King's College, London, UK and holds an ACA (ICAEW), Chartered Accountant qualification. Sath is also a Non-Executive member of the audit committee at The Institute of Cancer Research (ICR)."

No idea what you are on about D.

RNS ? Maybe the new BDO arriving September 1st ?

Or something else GLA